Aviva Systems Biology

Executive Summary

Aviva Systems Biology is a privately held life science reagent company headquartered in San Diego, founded in 2003. The company supplies over 20,000 validated ELISA kits and a broad portfolio of monoclonal, polyclonal, and recombinant antibodies targeting more than 7,000 proteins. It also offers custom protein and antibody production services to support biomedical research. Operating in the competitive antibodies and reagents market, Aviva differentiates itself through its extensive catalog of validated products and custom service capabilities. While the company is not publicly traded and lacks disclosed financial data, its long-standing presence and specialization in high-quality research tools position it as a reliable supplier for academic and pharmaceutical customers. Future growth may hinge on expanding its product portfolio, leveraging recombinant antibody technology, and entering adjacent markets such as diagnostics or companion diagnostics. Given the fragmented nature of the reagent industry and Aviva's niche focus, the company's prospects are stable but unspectacular without significant capital infusion or strategic pivot.

Upcoming Catalysts (preview)

• Q3 2026Launch of a next-generation recombinant antibody platform70% success
• Q4 2026Partnership with a major pharmaceutical company for custom antibody development50% success
• Q1 2027Expansion into diagnostic antibody production with CLIA certification30% success